TuisDRUG • CNSX
add
Bright Minds Biosciences Inc
Vorige sluiting
$121,54
Dagwisseling
$119,46 - $122,88
Jaarwisseling
$33,01 - $170,00
Markkapitalisasie
1,17 mjd CAD
Gemiddelde volume
791,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
CNSX
Marknuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (CAD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | — | — |
Bedryfskoste | 6,74 m | 325,10% |
Netto inkomste | -7,57 m | -15 349,58% |
Netto winsgrens | — | — |
Wins per aandeel | -0,97 | -9 800,00% |
EBITDA | — | — |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (CAD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 89,05 m | 53,80% |
Totale bates | 90,88 m | 55,62% |
Totale aanspreeklikheid | 1,60 m | 179,80% |
Totale ekwiteit | 89,28 m | — |
Uitstaande aandele | 9,79 m | — |
Prys om te bespreek | 10,60 | — |
Opbrengs op bates | -19,23% | — |
Opbrengs op kapitaal | -19,65% | — |
Kontantvloei
Netto kontantverandering
| (CAD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -7,57 m | -15 349,58% |
Kontant van bedrywe | -5,82 m | -289,18% |
Kontant van beleggings | — | — |
Kontant van finansiering | 13,39 m | -74,27% |
Netto kontantverandering | 6,14 m | -88,23% |
Beskikbare kontantvloei | -4,01 m | -339,54% |
Meer oor
Bright Minds Biosciences is an American pharmaceutical company which is developing serotonin 5-HT₂ receptor agonists for potential medical use.
It has a particular focus on serotonin 5-HT2C receptor agonists, for instance to treat rare epilepsies and other conditions. Another area of focus for the company is serotonergic psychedelics and non-hallucinogenic psychoplastogens.
The company was co-founded by Ian McDonald and Gideon Shapiro. The lead scientist at Bright Minds Biosciences was previously Alan Kozikowski. Bright Mind Biosciences was founded in 2017 and its headquarters are in New York City, New York. Wikipedia
Gestig
2017
Webwerf
Werknemers
26
